Woodmont Investment Counsel LLC bought a new position in shares of iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE – Free Report) during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund bought 5,574 shares of the company’s stock, valued at approximately $560,000.
Several other hedge funds also recently added to or reduced their stakes in IHE. Balance Wealth Partners LLC purchased a new stake in iShares U.S. Pharmaceuticals ETF in the third quarter valued at about $42,000. Root Financial Partners LLC acquired a new stake in iShares U.S. Pharmaceuticals ETF in the third quarter worth about $51,000. Congress Asset Management Co. purchased a new stake in shares of iShares U.S. Pharmaceuticals ETF during the third quarter worth about $56,000. Trust Co. of Vermont purchased a new stake in shares of iShares U.S. Pharmaceuticals ETF during the second quarter worth about $60,000. Finally, Turtle Creek Wealth Advisors LLC purchased a new stake in shares of iShares U.S. Pharmaceuticals ETF during the third quarter worth about $64,000.
iShares U.S. Pharmaceuticals ETF Stock Down 0.6%
IHE opened at $106.92 on Tuesday. The company has a market cap of $1.60 billion, a P/E ratio of 17.75 and a beta of 0.47. The firm’s 50-day moving average price is $102.42 and its 200-day moving average price is $94.85. iShares U.S. Pharmaceuticals ETF has a 52-week low of $75.03 and a 52-week high of $109.43.
iShares U.S. Pharmaceuticals ETF Profile
iShares U.S. Pharmaceuticals ETF, formerly iShares Dow Jones U.S. Pharmaceuticals Index Fund (the Fund), is an exchange traded fund. The Fund seeks investment results that correspond generally to the price and yield performance of the Dow Jones U.S. Select Pharmaceuticals Index (the Index). The Index measures the performance of the pharmaceuticals sector of the United States equity market, and includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins.
Featured Stories
- Five stocks we like better than iShares U.S. Pharmaceuticals ETF
- AbbVie’s Humira Era Is Fading, But Its New Growth Engines Face Another Test
- GLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge?
- Mortgage Rates Froze U.S. Housing, But These 3 Overseas Markets Still Pay Double Digits
- Big Tech Is Spending Billions on AI—These 5 Stocks Are Getting Paid
Want to see what other hedge funds are holding IHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE – Free Report).
Receive News & Ratings for iShares U.S. Pharmaceuticals ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares U.S. Pharmaceuticals ETF and related companies with MarketBeat.com's FREE daily email newsletter.
